NASDAQ:CMPS COMPASS Pathways (CMPS) Stock Price, News & Analysis $6.62 -0.10 (-1.49%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$6.35▼$6.7850-Day Range$5.95▼$8.0352-Week Range$5.01▼$12.75Volume725,180 shsAverage Volume558,611 shsMarket Capitalization$453.02 millionP/E RatioN/ADividend YieldN/APrice Target$47.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get COMPASS Pathways alerts: Email Address COMPASS Pathways MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside615.5% Upside$47.40 Price TargetShort InterestBearish6.84% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.35) to ($2.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.70 out of 5 starsMedical Sector830th out of 910 stocksPharmaceutical Preparations Industry384th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingCOMPASS Pathways has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCOMPASS Pathways has only been the subject of 4 research reports in the past 90 days.Read more about COMPASS Pathways' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.84% of the outstanding shares of COMPASS Pathways have been sold short.Short Interest Ratio / Days to CoverCOMPASS Pathways has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in COMPASS Pathways has recently increased by 21.56%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCOMPASS Pathways does not currently pay a dividend.Dividend GrowthCOMPASS Pathways does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMPS. Previous Next 1.1 News and Social Media Coverage Search Interest30 people have searched for CMPS on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.MarketBeat Follows10 people have added COMPASS Pathways to their MarketBeat watchlist in the last 30 days. This is an increase of 11% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, COMPASS Pathways insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.25% of the stock of COMPASS Pathways is held by insiders.Percentage Held by Institutions46.19% of the stock of COMPASS Pathways is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about COMPASS Pathways' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for COMPASS Pathways are expected to grow in the coming year, from ($2.35) to ($2.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of COMPASS Pathways is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of COMPASS Pathways is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCOMPASS Pathways has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about COMPASS Pathways' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About COMPASS Pathways Stock (NASDAQ:CMPS)COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Read More CMPS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMPS Stock News HeadlinesAugust 28, 2024 | americanbankingnews.comCOMPASS Pathways (NASDAQ:CMPS) Earns "Buy" Rating from HC WainwrightAugust 28, 2024 | globenewswire.comCompass Pathways to participate in three investor conferences in SeptemberSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 28, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for COMPASS Pathways (NASDAQ:CMPS)August 6, 2024 | finance.yahoo.comCOMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth ConferenceAugust 2, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)August 2, 2024 | markets.businessinsider.comCOMPASS Pathways Poised for Growth with Strong Financials and Strategic Psychedelic Program AdvancementsAugust 1, 2024 | globenewswire.comCompass Pathways announces second quarter 2024 financial results and business highlightsSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… July 31, 2024 | theglobeandmail.com1 Biotech Stock Under $10 That Could Surge 420%July 24, 2024 | msn.comRBC Capital Initiates Coverage of COMPASS Pathways plc - Depositary Receipt () (CMPS) with Outperform RecommendationJuly 24, 2024 | globenewswire.comCompass Pathways to announce second quarter financial results on August 1, 2024July 8, 2024 | seekingalpha.comCompass Pathways: Buy It For Its Promising Psychedelic Mental Health TherapiesJuly 8, 2024 | investorplace.com3 Next-Gen Drug Stocks Exploring Psychedelic FrontiersJuly 2, 2024 | investorplace.com3 Psychedelic Stocks to Buy on the Dip: Summer 2024June 26, 2024 | globenewswire.comCompass Pathways appoints Lori Englebert as Chief Commercial OfficerJune 24, 2024 | globenewswire.comCompass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceJune 12, 2024 | fool.comShould You Buy the Dip on Compass Pathways Stock?See More Headlines Receive CMPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMPS CUSIPN/A CIK1816590 Webwww.compasspathways.com Phone716-676-6461FaxN/AEmployees120Year Founded2016Price Target and Rating Average Stock Price Target$47.40 High Stock Price Target$120.00 Low Stock Price Target$16.00 Potential Upside/Downside+615.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.74% Return on Assets-47.90% Debt Debt-to-Equity Ratio0.13 Current Ratio12.03 Quick Ratio12.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.31 per share Price / Book2.00Miscellaneous Outstanding Shares68,381,000Free Float65,475,000Market Cap$453.02 million OptionableOptionable Beta2.27 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Kabir Kumar Nath M.A. (Age 60)M.B.A., CEO & Director Comp: $1.31MMr. Matthew Allen Owens (Age 47)General Counsel & Chief Legal Officer Comp: $684.51kDr. Guy Goodwin (Age 76)Chief Medical Officer Comp: $567kMs. Teri Loxam M.B.A. (Age 51)CFO, Principal Financial Officer & Principal Accounting Officer Dr. Greg Ryslik Ph.D.Chief Technology OfficerMr. Stephen D. SchultzSenior Vice President of Investor RelationsMr. Christopher WilliamsChief Communications OfficerMs. Anne BenedictChief People OfficerMr. Lars Christian Wilde (Age 39)Senior Advisor Mr. Trevor MillChief Development OfficerMore ExecutivesKey CompetitorsSage TherapeuticsNASDAQ:SAGEMacroGenicsNASDAQ:MGNXRepare TherapeuticsNASDAQ:RPTXTravere TherapeuticsNASDAQ:TVTXPraxis Precision MedicinesNASDAQ:PRAXView All CompetitorsInsiders & InstitutionsAffinity Asset Advisors LLCSold 527,356 shares on 8/15/2024Ownership: 0.732%Millennium Management LLCBought 78,700 shares on 8/15/2024Ownership: 0.000%Susquehanna Portfolio Strategies LLCSold 15,844 shares on 8/15/2024Ownership: 0.031%Logos Global Management LPBought 901,050 shares on 8/14/2024Ownership: 1.695%Renaissance Technologies LLCBought 247,500 shares on 8/9/2024Ownership: 0.386%View All Insider TransactionsView All Institutional Transactions CMPS Stock Analysis - Frequently Asked Questions How have CMPS shares performed this year? COMPASS Pathways' stock was trading at $8.75 at the beginning of 2024. Since then, CMPS shares have decreased by 24.3% and is now trading at $6.6250. View the best growth stocks for 2024 here. How were COMPASS Pathways' earnings last quarter? COMPASS Pathways plc (NASDAQ:CMPS) released its quarterly earnings data on Thursday, August, 1st. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.03. When did COMPASS Pathways IPO? COMPASS Pathways (CMPS) raised $100 million in an IPO on Friday, September 18th 2020. The company issued 6,700,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg served as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are COMPASS Pathways' major shareholders? COMPASS Pathways' top institutional investors include ARK Investment Management LLC (3.07%), Logos Global Management LP (1.69%), Affinity Asset Advisors LLC (0.73%) and Sumitomo Mitsui Trust Holdings Inc. (0.42%). Insiders that own company stock include Ekaterina Malievskaia, George Jay Goldsmith and David Y Norton. View institutional ownership trends. How do I buy shares of COMPASS Pathways? Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of COMPASS Pathways own? Based on aggregate information from My MarketBeat watchlists, some other companies that COMPASS Pathways investors own include Nikola (NKLA), Vaxart (VXRT), Beyond Meat (BYND), Evofem Biosciences (EVFM), GrowGeneration (GRWG), McDonald's (MCD) and Plug Power (PLUG). This page (NASDAQ:CMPS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways plc Please log in to your account or sign up in order to add this asset to your watchlist. Share COMPASS Pathways With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
